References
- Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
- Cornely OA, Maertens J, Bresnik M, Herbrecht R. Liposomal amphotericin B as initial therapy for invasive filamentous fungal infections: a randomized, prospective trial of a high loading dose versus standard dosing. Blood 2005; 106: A3222
- Raad, I, Chapman, Bradsher, R, et al. Posaconazole savage therapy for invasive fungal infections. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 30, October–2 November, 2004. Abstract M-669.
- Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
- Maertens, J, Glashmacher, A, Herbrecht, R, et al. Multicenter, noncomparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis refractory or intolerant to prior therapy: final data. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 16–19, December, 2005. Abstract M-954.
- Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43(Suppl. 1)S49–58
- Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322–330
- Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
- Patterson, T. Defining invasive fungal infections: new directions. Aspergillosis and other filamentous fungi. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 16–19, December, 2005. Abstract 1785
- de Pauw BE, Patterson TF. Should the consensus guidelines’ specific criteria for the diagnosis of invasive fungal infection be changed?. Clin Infect Dis 2005; 41(Suppl. 6)S377–380
- De Pauw, B, Walsh, T, Patterson, T, , et al. Defining invasive infections: new directions. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 16–19, December, 2005. Abstract 1789.
- Chamilos, G, Luna, M, Lewis, EE, , et al. Invasive aspergillosis in autopsy of patients with hematological malignancies (2000–2004). In: 2nd Advances Against Aspergillosis Conference. Athens, 22–25, February, 2005. Abstract 136.
- Anaissie, E. Controversies in antifungal trial design. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 16–19, December, 2005. Abstract M-715.